Research Article
Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma
Table 3
PFS between challenge and rechallenge.
| Time to progression after first ipilimumab treatment | Number of cases (%) |
| <6 months | 3 (14) | 6–12 months | 15 (68) | >12 months | 4 (18) |
|
|